First Blood Collection Tube for IVD Genomic DNA Testing Now Available

Jan 26, 2014

Oxford, United Kingdom (January 28, 2014) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the commercial availability of the CE-marked PAXgene® Blood DNA Tube in Europe. The PAXgene® Blood DNA Tube is the first blood collection tube designed specifically for in vitro diagnostic (IVD) genomic DNA testing. The product was developed by PreAnalytiX GmbH, a joint venture between BD and QIAGEN.

DNA testing has advanced significantly since the publication of the first draft of the human genome in 2000. While swab and saliva samples are popular, blood remains the sample of choice for clinical diagnostic testing and identification of new biomarkers for disease research.

To improve the collection of DNA in these applications, the PAXgene® Blood DNA Tube performance has been comprehensively analysed. “The validated performance data we provide to clinical scientists for the PAXgene® Blood DNA Tube should reduce the chances of preanalytical error, ensuring the best quality sample for accurate IVD test performance and for blood DNA storage related to the identification of new biomarkers of disease or drug actions”, comments Frank Augello, General Manager, PreAnalytiX GmbH.

The PAXgene® Blood DNA Tube is a 2.5 ml blood collection tube that stabilizes genomic DNA with validated time and temperature parameters. The tube incorporates workflow efficiency features including a 2D bar code on the label and a tube closure that clearly identifies this unique DNA tube.

The PAXgene® Blood DNA Tube is a constituent of a complete molecular diagnostic portfolio of PreAnalytiX GmbH products comprising DNA isolation kits, automation and analysis equipment. The initial target customers for the PAXgene® Blood DNA Tube are those requiring validated high quality blood DNA - blood DNA testing laboratories and biorepositories.

For more information, contact your local BD customer services office (www.bd.com) or visit www.preanalytix.com/product-catalog/blood/dna/products/paxgene-blood-dna-tube-ce/.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. 

For more information on BD, please visit bd.com.

About PreAnalytiX GmbH

PreAnalytiX GmbH, a joint venture between BD and QIAGEN, develops, manufactures and sells integrated and standardized systems for collection, stabilization and purification of RNA, microRNA and DNA from blood, bone marrow and tissue specimens. The Company serves healthcare institutions, academic researchers, clinical laboratories and the pharmaceutical industry with a broad array of manual and automated products. For more information on PreAnalytix BmbH, visit www.preanalytix.com.

About QIAGEN

QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. For more information on QIAGEN, visit www.qiagen.com.

Heather Williams

+ 44 (0) 7557 001205
Email

Back to News Releases